ArticleFrontiers in pediatrics2025
The protective role of steroids on coronary arteries in the acute phase of Kawasaki disease for high risk patients: a retrospective study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Evolving Role of Corticosteroids in Kawasaki Disease: Evidence, Mechanisms, and Clinical Implications.Pediatric cardiology · 2026Review
- A case report of severe Mycoplasma pneumoniae pneumonia complicated by plastic bronchitis and Kawasaki disease.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The incidence of coronary artery aneurysms in Kawasaki disease has been increasing for reasons that remain unclear. Recently the use of corticosteroids in KD has been reconsidered for high-risk patients. To evaluate their effectiveness as first line therapy in combination with IVIG and aspirin for selected KD patients, we performed this retrospective single-center study. Methods: We retrospectively analyzed KD patients (aged 30 days to 18 years) who were hospitalized at the Bambino Gesù Children's Hospital between December 2007 and February 2023. The patients were classified as "high risk (HR)" or "low risk (LR)" for IVIG resistance and/or developing CAA according to the Italian guidelines and were stratified by treatment. We also analyzed changes in AHA risk class in the HR-S and HR-NS groups. Furthermore, to obtain a single representative Z-score for each patient, we introduced a novel calculation method: a. Z-MAX: the maximum value of the scores between the three coronary arteries. b. Z-SUM: the sum of the single Z-scores of the three coronary arteries. Results: 374 patients were enrolled, 78 with CAA and 296 without CAA. Of those, 195 patients were classified as HR and all subsequent analyses in this study were exclusively conducted on this subgroup. At the end of the eight weeks, the HR-S group showed a significant reduction in coronary artery dimensions expressed as Z-score (reduction of 65% in RCA, 63% in LMCA, and 36.5% in LAD). In contrast, the HR- NS group showed an increase in the dimension of two arteries (RCA increased by 17% and LAD increased by 15%) and a slight reduction of LMCA (7.5%). Conclusion: First-line therapy with IVIG plus steroids in HR-KD patients reduces the development of CAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.